

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: The Yield Growth Corp. (the "Issuer").

Trading Symbol: BOSS

Number of Outstanding Listed Securities: 114,326,474 common shares (plus 46,685,498 common shares reserved for issuance in the form of 31,551,670 warrants and 15,133,828 options)

Date: February 1, 2020

Report on Business

1. **Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.**

On January 4, 2020, the Issuer's subsidiary, Flourish Mushroom Labs Inc. ("Flourish") entered into a binding letter of intent with Acres Agricultural Canada Corp. ("Acres") to jointly form a company in Saint Vincent and the Grenadines, Acres Flourish Labs (SVG) Ltd ("AF Labs"), to build a laboratory for the cultivation of psilocybin mushrooms and for research and development into compounds and therapeutic use of psychedelic mushrooms.

On January 9, 2020, the Issuer's subsidiary Flourish announced it had appointed seasoned sales expert Amber Allen as VP Sales of Flourish. Ms. Allen has decades of experience working with distributors to grow a multitude of brands in the edible mushroom and other wellness spaces. Ms. Allen has also worked with other wellness companies: My Matcha Life, Sun Warrior, Mikei Red Reishi, and Thursday Plantation.

On January 14, 2020, the Issuer's subsidiary Flourish announced it had appointed Dr. William Panenka, MD, MSc, FRCPC (Neurology and Psychiatry) as Chair of its Medical Advisory Board. Dr. Panenka is a dually boarded neurologist and Psychiatrist and Canadian Institute of Health Research funded academic faculty at the University of British Columbia. He did a post doctoral fellowship at UBC and Harvard University. He maintains an internationally recognized research program in brain injury, mental health, and addictions. Dr. Panenka is the founder and a director of Translational Life Sciences Inc. ("TLS"), a company that aims to develop products using restricted substances for clinical applications.

On January 16, 2020, the Issuer's subsidiary Flourish announced it had appointed Jeff B. Smith as a director and as Chairman of the Board. Mr. Smith was an executive for over 20 years at Johnson & Johnson Consumer Companies. His roles included Chief Transformation Officer, Group Chairman, Consumer North America and President, US Skincare. Mr. Smith holds an MBA from Edwards School of Business, University of Saskatchewan and a BA in Economics, University of Saskatchewan. He joins the Flourish board after acting as Chairman of the Issuer's advisory board for approximately one year, a position which he continues to hold.

The Issuer announced several management changes on this date as well, including, Amy Frankel's change of role and title from VP, Licensing, General Counsel, and Corporate Secretary to Corporate Secretary, General Counsel and Vice President, People. Tom Bond changed his role with the Issuer to advisor and is no longer a director of the board or the Issuer's subsidiary Urban Juve Provisions. Rick Huang joins the Issuer's board of directors and Urban Juve's board of directors in addition to his role as CFO at the Issuer and Flourish.

On January 21, 2020 the Issuer announced that Flourish entered into an agreement to acquire approximately 18% of TLS. The terms of the binding letter of intent are that Flourish shall issue 15,000,000 units of Flourish with each unit consisting of one common share and one share purchase warrant to acquire an additional common share in the capital of Flourish at a price of \$0.05 per share. In exchange, Flourish shall acquire approximately 18% of the TLS stock at a deemed cost of \$750,000. The transaction assumes a post-closing valuation of Flourish of approximately \$7,000,000. the Issuer shall not issue any securities as part of the transaction.

On January 23, 2020 the Issuer announced an overall consumer rating of 4.5 stars out of 5 on IPSY.com for consumer reviews for Urban Juve's Ultra-Hydrating lip balm with over 15,000 reviews.

2. Provide a general overview and discussion of the activities of management.

Please see Item 1 above.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Please see Item 1 above.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

Please see Item 1 above.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the

disposition was to a Related Person of the Issuer and provide details of the relationship.

Please see Item 1 above.

8. **Describe the acquisition of new customers or loss of customers.**

Please see Item 1 above.

9. **Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.**

Please see Item 1 above.

10. **Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.**

Please see Item 1 above.

11. **Report on any labour disputes and resolutions of those disputes if applicable.**

None.

12. **Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.**

None.

13. **Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.**

None.

14. **Provide details of any securities issued and options or warrants granted.**

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾
Stock Options	1,300,000	January 2, 2020: 1,300,000 stock options granted to various directors and officers at an exercise price of \$0.195 per common share for a maximum period of 5 years (or earlier in accordance with the Issuer's stock option plan)	Not applicable
Special Warrants	1,816,666	January 3, 2020: 1,816,666 special warrants issued pursuant to a private placement at a price of \$0.15 per special warrant. Each special warrant is exercisable without further payment into one unit of the Issuer pursuant to the terms and conditions of the	Net proceeds of \$272,499.90 to be used as set out in the Prospectus Supplement.

		prospectus supplement filed on January 9, 2020	
Units	1,731,291	January 3, 2020: 1,731,291 units issued pursuant to the conversion of the special warrants issued on December 20, 2019. Each unit consists of one common share and one common share purchase warrant exercisable at \$0.265 until December 20, 2020.	
Special Warrants	666,666	January 7, 2020: 666,666 special warrants issued pursuant to a private placement at a price of \$0.15 per special warrant. Each special warrant is exercisable without further payment into one unit of the Issuer pursuant to the terms and conditions of the prospectus supplement filed on January 9, 2020	Net proceeds of \$99,999.90 to be used as set out in the Prospectus Supplement.
Stock Options	400,000	January 13, 2020: 400,000 stock options granted to a consultant at an exercise price of \$0.28 per common share for a maximum period of 5 years (or earlier in accordance with the Issuer's stock option plan)	Not applicable
Common Shares	50,000	January 13, 2020: 50,000 common shares issued at a price of \$0.10 per share pursuant to an option exercise	Net proceeds of \$5,000 to be used for general working capital
Units	2,483,332	January 14, 2020: 2,483,332 units issued pursuant to the conversion of the 1,816,666 special warrants issued on January 3, 2020 and the 666,666 special warrant issued on January 7, 2020. Each unit consists of one common share and one common share	

FORM 7 – MONTHLY PROGRESS REPORT

January 2015

Page 4

		purchase warrant exercisable at \$0.195 until July 3, 2020 and July 7, 2020 respectively.	
Stock Options	200,000	January 15, 2020: 200,000 stock options granted to an employee at an exercise price of \$0.285 per common share for a maximum period of 5 years (or earlier in accordance with the Issuer's stock option plan)	Not applicable
Common Shares	666,666	January 20, 2020: 666,666 common shares issued at a price of \$0.195 per share pursuant to a warrant exercise	Net proceeds of \$129,999.87 to be used for general working capital
Common Shares	500,000	January 22, 2020: 500,000 common shares issued at a price of \$0.195 per share pursuant to a warrant exercise	Net proceeds of \$97,500 to be used for general working capital
Common Shares	400,000	January 24, 2020: 400,000 common shares issued at a price of \$0.195 per share pursuant to a warrant exercise	Net proceeds of \$78,000 to be used for general working capital
Common Shares	136,000	January 29, 2020: 136,000 common shares issued at a price of \$0.195 per share pursuant to a warrant exercise	Net proceeds of \$26,520 to be used for general working capital
Common Shares	500,000	January 31, 2020: 500,000 common shares issued at a price of \$0.195 per share pursuant to a warrant exercise	Net proceeds of \$97,500 to be used for general working capital

(1) State aggregate proceeds and intended allocation of proceeds.

15. **Provide details of any loans to or by Related Persons.**

None.

16. **Provide details of any changes in directors, officers or committee members.**

Please see item 1 above.

17. **Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.**

On October 17, 2018, The Cannabis Act came into force in Canada and recreational cannabis is now available to legal adults (aged 18 or 19 depending on the province or territory) for purchase, growth, or use in limited quantities. On October 17, 2019, additional legislation came into force in Canada allowing and regulating the use and sale of Cannabis topical and edible products.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated February 1, 2020.

Penny White
Name of Director or Senior Officer

"Penny White"
Signature

Chief Executive Officer and
President
Official Capacity

Issuer Details Name of Issuer The Yield Growth Corp.	For Month End January 2020	Date of Report YY/MM/DD 20/02/01
Issuer Address Suite 200, 1238 Homer Street		
City/Province/Postal Code Vancouver, British Columbia V6B 2Y5	Issuer Fax No. N/A	Issuer Telephone No. 833.514.2677
Contact Name Penny White	Contact Position President, CEO, and Director	Contact Telephone No. 833.514.2677
Contact Email Address penny@yieldgrowth.com	Web Site Address www.yieldgrowth.com	